Tesamorelin: approved uses, evidence and access
Heads up: Peptide Clarity Guide works with partners, and a few buttons below pay us if you join (you pay the same). Who pays plays no part in the order here, or in what we write. How we earn.
The short answer
Egrifta is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its label does not indicate general weight-loss management. Egrifta is ineligible for the 503A/503B compounding exemptions. Prescribing an approved product off label and authorized research are separate questions; neither establishes a commercial compounded alternative.
Definition
Tesamorelin is a lab-made analog of growth hormone-releasing factor (GHRF). It prompts the pituitary to release growth hormone. The reviewed current US approved formulations are Egrifta SV and Egrifta WR.
Key facts
| Fact | Detail |
|---|---|
| Class | Growth hormone-releasing factor analog |
| Approved as | Egrifta (first approved November 10, 2010); current forms Egrifta SV and Egrifta WR, which aren't substitutable[4] |
| Labeled use | Reducing excess abdominal fat in adults with HIV and lipodystrophy[3] |
| Label limits | Not indicated for weight loss; long-term heart safety not established[3] |
| Compounding | Not eligible since March 23, 2020, when it became a biologic under a deemed license[6] |
| Who prescribes | Clinicians for the labeled use; off-label prescribing requires a separate benefit-risk judgment |
Egrifta’s approval concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Evidence from that population should not become a promise of general weight loss, muscle gain or healthy aging. An approved product’s off-label prescription, a routine compounded product and an authorized investigational supply are different pathways.
A growth hormone-releasing peptide with a brand-name label
Tesamorelin is a peptide that signals the pituitary to release growth hormone. It works on the same signal as sermorelin, with a different molecule and a different regulatory life.
Tesamorelin has current Egrifta labeling and large HIV-associated lipodystrophy trials. Sermorelin has a different approval history and a separate, smaller adult evidence base. Neither is approved for anti-aging.
What it's approved for: belly fat in HIV-associated lipodystrophy
Egrifta is approved "for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" [3]. That's the whole indication.
The label adds three limits. Long-term cardiovascular safety hasn't been established. It's "not indicated for weight loss management as it has a weight neutral effect." And there's no data that it improves adherence to HIV medicines [3].
The label also tells clinicians to weigh continuing treatment in people whose visceral fat hasn't dropped [3]. In other words, it's meant to be judged on a measured result, not on how someone feels.
Why the usual compounding exemptions do not apply
On March 23, 2020, Egrifta's approval was deemed a biologics license, and biologics aren't eligible for the 503A and 503B compounding exemptions [6] [5].
FDA's notice to compounders put it plainly: from that date, transitioning biological products "will not be eligible for the exemptions for compounded drugs under sections 503A and 503B" [6]. This does not authorize a routine commercial preparation from bulk tesamorelin. FDA separately discusses conditional mixing, dilution or repackaging of licensed biological products; that is not a general 503A/503B compounding exemption.
The full legal answer, including approved-product prescribing and investigational pathways, is in can you get tesamorelin legally. Why that leaves no low-cost compounded version is explained in tesamorelin's brand-only status.
Tesamorelin by goal: one approved effect, a few off-label findings
Approval trials support the specific abdominal-fat indication. Other trials examined liver fat, cognition, body composition and sleep in defined populations. Their findings do not establish broad wellness benefits.
| Goal | Evidence | Read more |
|---|---|---|
| Deep (visceral) belly fat | Approved use. 26 weeks: -15.2% vs +5.0% on placebo in 412 adults with HIV [10]; held at 52 weeks in those who stayed on it [11] | How long tesamorelin takes |
| Liver fat | Two randomized studies in people with HIV: a six-month study enrolled 50, with 48 treated, and a net 2.9-percentage-point reduction in liver lipid-to-water percentage; a separate twelve-month study enrolled 61, with 60 treated, and reported a 37% relative reduction [12][13] | Study populations and liver-fat measures differ; no approved liver-fat indication |
| Cognition | Outside the approved indication. 152 older adults, 20 weeks: favorable primary cognitive-composite analysis [14] | One trial |
| Lean tissue and muscle | The 20-week older-adult trial also measured increased DXA lean mass; this does not establish strength or performance gains [14] | Does tesamorelin build muscle? |
| Testosterone | Not an outcome in the approval trials | Does tesamorelin raise testosterone? |
| Appetite | Not an outcome in the approval trials | Does tesamorelin affect appetite? |
| Sleep and energy | Sleep quality did not improve in the older-adult trial; a reliable general-energy benefit is not established [14] | Sleep and recovery shortlist |
| Height | Not an approved pediatric height treatment; adult findings do not establish a height benefit | n/a |
| Weight loss | The label says it's weight neutral and not for weight loss [3] | Body-composition shortlist |
Two things to notice. The main trials enrolled people with HIV, not healthy adults chasing a leaner look. And in the cognition trial, fasting insulin rose 35% in the group with mild cognitive impairment, within the normal range [14], one more sign that growth hormone signaling has trade-offs.
Baker’s trial randomized 152 adults aged 55–87, including healthy participants and people with mild cognitive impairment. At 20 weeks, DXA lean mass rose 3.7% and body fat fell 7.4%; body weight, mood and sleep quality did not differ significantly. These are body-composition and questionnaire findings, not demonstrated muscle strength, dementia prevention or a weight-loss indication [14].
It targets fat around the organs, not the fat under your skin
Tesamorelin's effect is on visceral fat, the deep fat around the organs. Fat just under the skin of the belly barely changed in the phase 3 trials.
A pooled analysis of the two phase 3 trials covered 806 adults. At 26 weeks, visceral fat fell with a treatment effect of -15.4%. Belly fat under the skin changed by -0.6%, not a significant difference [11]. Waist size, triglycerides and cholesterol also improved. People also rated their belly appearance better.
For those who stayed on it, the visceral-fat drop held at 52 weeks, at 17.5% below baseline [11]. That's the honest shape of the result: a specific fat depot, in a specific group, while you keep taking it. It's also why the label calls it weight neutral.
It raises IGF-1, which the label watches
Tesamorelin raises IGF-1, the hormone growth hormone drives. IGF-1 rose 81% in the main trial and 117% in the cognition trial [10] [14].
That's the mechanism doing its job, and it's also why the label lists elevated IGF-1 as a warning and tells clinicians to monitor it [3]. It's one reason tesamorelin is a prescription drug with follow-up, not something to take on your own.
Side effects on the label
The label's most common side effects are joint pain, injection-site redness and itching, limb pain, swelling and muscle aches. Two numbers stand out.
- Injection-site reactions: 25% on Egrifta vs 14% on placebo in the first 26 weeks [3].
- Diabetes risk: HbA1c reaching 6.5% or higher in 5% vs 1% on placebo [4].
- Warnings: possible increased risk of tumors (it's contraindicated with active cancer), raised IGF-1, fluid retention and hypersensitivity reactions [3].
- Who can't take it: people with a disrupted pituitary axis, active cancer or a known allergy to it, and pregnant women [3].
Combining tesamorelin with other drugs
Start by identifying the exact approved product. Egrifta’s labeling does not make off-label prescribing categorically unlawful, but it also does not establish a combination’s benefit or safety. A commercial bulk-compounded preparation does not gain the 503A/503B exemptions [1] [6].
Combinations people ask about, with ipamorelin, sermorelin, semaglutide or tirzepatide, are covered in can you combine tesamorelin and tesamorelin and ipamorelin together. The reviewed evidence does not establish the safety or benefit of adding a GLP-1 to tesamorelin. Ipamorelin and CJC-1295 have separate routine-compounding restrictions; see ipamorelin.
Tesamorelin and sermorelin: same signal, different rules
Both prompt the pituitary to release growth hormone. They differ on almost everything else that affects you.
| Tesamorelin | Sermorelin | |
|---|---|---|
| FDA status | Approved as Egrifta for one use | Not approved today; former Geref approval withdrawn in 2009; FDA later found the withdrawal was not for safety or effectiveness |
| Can it be compounded? | Not under the 503A/503B exemptions | Conditional compounding requirements apply |
| Human evidence | Large trials in HIV and a separate older-adult trial | Small studies in different populations, including a 31-man HIV trial; modified analogs must be distinguished |
| Sold through telehealth programs | No lawful compounded version | Yes, in several forms |
So the two aren't interchangeable, even though ads often treat them that way. Sermorelin's own evidence and costs are on sermorelin.
Tesamorelin's FDA timeline
Tesamorelin went from a new approval in 2010 to a biologic in 2020, with new formulations along the way.
| Date | What happened | What it means for you |
|---|---|---|
| November 10, 2010 | Egrifta approved, application 022505 [5] | Original Egrifta approval |
| March 23, 2020 | Egrifta's approval deemed a biologics license; biologics do not qualify for 503A/503B exemptions [6] [5] | No routine 503A/503B compounding exemption |
| March 25, 2025 | Egrifta WR approved: new formulation and multiple-dose presentation [9] | A second current form |
What a prescriber can offer instead
A clinician can prescribe an approved Egrifta product for the labeled use and may consider an off-label use under medical judgment. That does not mean such use has proven benefit or insurance coverage. Authorized research is a separate pathway, not a commercial compounded substitute [1] [2].
- Sermorelin is a compounded GHRH analog sold through telehealth. Its adult evidence is small; see sermorelin.
- Body composition has better-studied prescription options. The body-composition shortlist lays them out.
- Sleep and recovery programs are on the sleep and recovery shortlist.
If someone offers you tesamorelin outside an Egrifta prescription, ask what it is and who made it. A research-use label alone does not authorize patient treatment. Investigational supply requires the applicable research authorization; it is not established by a registry listing or a storefront claim [2].
Research on Tesamorelin
Tesamorelin combinations: what's been studied and what the label warns
People search for tesamorelin plus almost everything. Here's the short answer for each pairing: what the cited studies establish, what the label says, and where each partner drug stands legally.
Can you get tesamorelin legally? The one route, and what to do instead
Search for tesamorelin and you'll find vials, kits and clinic menus. Only one of those is a legal way to get it.
Does tesamorelin increase appetite? No, and it isn't a weight-loss drug
Tesamorelin shrinks one kind of belly fat without touching hunger or the scale much. Here's how that works, and what the label warns about.
Does tesamorelin help build muscle? A small effect in a narrow group
More growth hormone sounds like more muscle. The trials that measured it found something much smaller, in a very specific group.
Does tesamorelin increase testosterone? No, it targets growth hormone
Plenty of pages call tesamorelin a testosterone booster. Its FDA label says otherwise. Here's what it changes, what it doesn't, and where to look if low testosterone is the worry.
Tesamorelin and ipamorelin together: untested and not legally compounded
The pairing shows up on clinic menus and in paid promotional posts. Here's what's actually known, and why a pre-mixed blend has nowhere legal to come from.
Tesamorelin cost: brand-only pricing, insurance, and why there's no cheap version
There's one maker, one brand and no cheaper copy. That shapes every part of what you'd pay.
How long tesamorelin takes to work: the trial checkpoints
The trials give one clear checkpoint, at six months, and an answer most pages skip: what happened when people stopped.
Frequently asked
- Is tesamorelin FDA approved?
- Yes, as Egrifta, only for excess belly fat in adults with HIV-associated lipodystrophy.
- Can tesamorelin be compounded?
- Egrifta is ineligible for the 503A and 503B compounding exemptions after the biologics transition. That is distinct from an approved-product prescription or an authorized investigation.
- Can tesamorelin make you taller?
- It is not approved as a pediatric height treatment. Its adult trial findings do not establish a height benefit.
- Does tesamorelin give you energy?
- A reliable energy benefit for general wellness is not established. A separate older-adult trial measured sleep quality and found no significant improvement.
- Can you take tesamorelin with semaglutide?
- The reviewed evidence does not establish the pair’s benefit or safety. Ask the prescriber about the exact approved product, off-label rationale and monitoring; commercial compounding and investigational use are separate questions.
- Is tesamorelin a weight-loss drug?
- No. The label says it isn't indicated for weight-loss management. It targets deep belly fat in one group of patients.
Sources
- [1] FDA: Understanding unapproved use of approved drugs. Undated source. FDA
- [2] FDA: Investigational New Drug application. Undated source. FDA
- [3] EGRIFTA SV (tesamorelin) for injection, prescribing information (2026). DailyMed label
- [4] EGRIFTA WR (tesamorelin) for injection, prescribing information (2026). DailyMed label
- [5] List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020. FDA
- [6] Notice to Compounders: Changes That Affect Compounding on March 23, 2020. FDA
- [7] Drugs@FDA: application 022505, Egrifta (tesamorelin acetate) (2026). FDA
- [8] EGRIFTA SV prescribing information (revised November 2018) (2018). FDA
- [9] Supplement approval letter, BLA 022505/S-020 (Egrifta WR), 2025. FDA
- [10] Falutz J. Metabolic effects of a growth hormone-releasing factor in patients with HIV (2007). PMID 18057338
- [11] Falutz J. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data (2010). PMID 20554713
- [12] Stanley TL. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial (2014). PMID 25038357
- [13] Stanley TL. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial (2019). PMID 31611038
- [14] Baker LD. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial (2012). PMID 22869065